Motixafortide bulk supplier for pharma manufacturers

Motixafortide 62 mg per vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 62 mg per vial

Reference Brands: Aphexda (USA/EU)

Motixafortide is a subcutaneous injectable drug used in combination with filgrastim to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. It works by blocking the CXCR4 receptor, which releases stem cells from the bone marrow. This therapy is used in patients who require stem cell collection.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Motixafortide — third party manufacturing & bulk supply

Motixafortide 62 mg per vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Motixafortide is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Motixafortide listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Motixafortide →

Back to Listing

Frequently Asked Questions

Motixafortide is listed as Injection in 62 mg per vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Motixafortide is referenced against Aphexda (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.